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The neuropeptide alpha-melanocyte stimulating hormone (α-MSH) has an important role in modulating immunity and
homeostasis. The production of IFN-γ by eﬀector T cells is suppressed by α-MSH, while TGF-β production is promoted in the
same cells. Such α-MSH-treated T cells have immune regulatory activity and suppress hypersensitivity, autoimmune diseases, and
graft rejection. Previous characterizations of the α-MSH-induced Treg cells showed that the cells are CD4+ T cells expressing the
same levels of CD25 as eﬀector T cells. Therefore, we further analyzed the α-MSH-induced Treg cells for expression of eﬀector and
regulatory T-cell markers. Also, we examined the potential for α-MSH-induced Treg cells to be from the eﬀector T-cell population.
We found that the α-MSH-induced Treg cells are CD25+ CD4+ T cells that share similar surface markers as eﬀector T cells, except
that they express on their surface LAP. Also, the α-MSH treatment augments FoxP3 message in the eﬀector T cells, and α-MSH
induction of regulatory activity was limited to the eﬀector CD25+ T-cell population. Therefore, α-MSH converts eﬀector T cells
into Treg cells, which suppress immunity targeting speciﬁc antigens and tissues.
1.Introduction
The melanocortin pathway is a highly conserved family
of receptors and ligands that have important roles in
regulating metabolism, pigmentation, and immunity [1–3].
The prototypic melanocortin, alpha-melanocyte stimulating
factor (α-MSH), suppresses inﬂammation mediated by both
innate and adaptive immunity. The neuropeptide α-MSH
inhibits NF-kB activation by blocking the intracellular
signaling pathways initiated by TLR, scavenging, IL-1, and
TNFα receptors in macrophages, dendritic cells, and neu-
trophils through the melanocortin 1 receptor (MC1r) and
the melanocortin 3 receptor (MC3r) [4–11]. In addition,
α-MSH induces MC1r expression, and transcription of
proopiomelanocortin hormone in monocytes establishing a
self-perpetuating immunosuppressive autocrine loop [12].
Because the serum levels of α-MSH increase during the
acute phase of inﬂammation [13] and the anti-inﬂammatory
activity of α-MSH has an antagonist relationship with
proinﬂammatory mediators [2] suggests that α-MSH has an
important role in the resolution of inﬂammation and the
maintenance of immune homeostasis.
The analysis of the molecular mechanisms of ocular
immuneprivilegedemonstratestheimportanceofα-MSHin
preventing and suppressing inﬂammation within the healthy
eye [14, 15]. Within the ocular microenvironment, the
constitutively present α-MSH has an important role in sup-
pressing the activation of eﬀector T-cells, and in the regional
induction of Treg cells [14, 16–19]. Also, the melanocortin
pathway has a role in resolving ocular autoimmune disease
in converting a systemic eﬀector T cell response into a
regulatory T-cell response speciﬁc to ocular autoantigens
[20, 21]. Injections of α-MSH peptide or DNA plasmids
encodingforα-MSHhavebeenusedasexperimentaltherapy
to suppress graft rejection, inﬂammation, and autoimmune
diseases in the eye and in the CNS [22–28]. Also, Treg cells
induced by α-MSH have been used in adoptive transfer
experiments to suppress hypersensitivity, autoimmunity,
and graft rejection [17, 29, 30]. These adoptive transfer
experiments demonstrated that the activation of regulatory
activity was antigen speciﬁc; however, the mechanisms of
suppression were general and most likely mediated by TGF-β
produced by the Treg cells [17].2 Journal of Transplantation
We have previously demonstrated that α-MSH not only
suppresses IFN-γ production by activated eﬀector T cells
already programmed to be Th1 cells, but also made the T
cells become functional CD25+ CD4+ Treg cells that produce
only TGF-β [16, 17, 29]. To see the eﬀects of α-MSH on the
eﬀector T cells; it is required for the eﬀector T cells to be
stimulated through their T-cell receptor (Tcr)-stimulation
either by antigen presenting cells or by cross-linking using
anti-CD3 antibody 2C11. The eﬀects of α-MSH is not
through the Tcr, but through the melanocortin 5 receptor
(MC5r) [17]. Blocking MC5r prevents α-MSH induction of
regulatory activity in the activated T cells. Further analysis
of the α-MSH-induced Treg cells show that the Treg cells
after activation express message for IFN-γ and TGF-β at the
same level as untreated activated Th1 cells [16]. Staining for
intracellularIFN-γ proteinshowssimilarlevelsoftheprotein
in α-MSH-treated and -untreated eﬀector T cells [31]. Treat-
ment with α-MSH enhances ubiquitination of intracellular
IFN-γ protein preventing the T cells from secreting IFN-γ
while allowing for free production and secretion of TGF-β.
This demonstrated that α-MSH manipulates eﬀector CD4+
T cells as they are Tcr-stimulated by altering the secretion
of speciﬁc cytokines to make the T cells suppress or regulate
immunogenic inﬂammation. This is not a transient eﬀect,
since it is possible to adoptively transfer these α-MSH-
induced Treg cells and eﬀectively suppress hypersensitivity,
autoimmune disease, and graft rejection in vivo [17, 29, 30].
In this work, we assayed the α-MSH-induced Treg cells
and found that they are CD25+ CD4+ T cells, producing
TGF-β and expressing on their surface latency-associated
peptide of TGF-β (LAP). In addition, the results further
support the potential for α-MSH to convert eﬀector T cells
into functional Treg cells.
2.MaterialsandMethods
2.1. In Vitro Simulation and α-MSH Treatment of Eﬀector
TC e l l s . C57BL/6 mice were purchased from Jackson Labo-
ratories (Bar Harbor, ME). All mice were treated with the
approval of the Schepens Eye Research Institute and the
Boston University School of Medicine Institutional Animal
Care and Use Committees. The immunization of the mice
and isolation of lymph node T cells were as we have done
before [14, 17, 30, 31]. The mice were injected with 50μL
of Complete Freund’s Adjuvant fortiﬁed with 10mg/mL des-
iccated Mycobacterium tuberculosis into the footpad. Seven
days later; the draining popliteal lymph node was collected
to obtain eﬀector T cells. The lymph nodes were removed
and placed in 5% fetal bovine serum (FBS) in RPMI-1640
supplemented with 10μg/mL Gentamycin (Sigma, St Louis,
MO), 10mM HEPES, 1mM Sodium Pyruvate (BioWhit-
taker, Walkersville, MD), and 1X Nonessential Amino Acids
(NEAA). The lymph nodes were made into a single cell
suspension, depleted of red blood cells, and washed with
serum free media (SFM), RPMI-1640 supplemented with
0.2% ITS+1-media supplement (Sigma), and 0.1% bovine
serum albumin (BSA). The CD4+ T cells were isolated from
the cell suspension using negative selection CD4 columns
(R&DSystems,Minneapolis,MN).TheisolatedCD4+ Tcells
(98% CD4+ by ﬂow cytometry analysis) were plated into
the wells of 96-well plate at 1 × 106 cells per well. Into
each well was added 1μg anti-CD3 (Tcr) 2C11 antibody
(BD Biosciences, San Diego, CA), and α-MSH (Bachem,
Torrance, CA) at a physiological concentration of 30pg/mL
[14]. The cultures were incubated at 37◦C, 5% CO2 until
collected for the assays described below.
2.2. Flow Cytometry Staining. Antibodies used for ﬂow cy-
tometry staining were anti-CD25-PerCP-Cy5.5 (BD Bio-
sciences), anti-GITR-FITC (R&D Systems), anti-CTLA4-
FITC (R&D Systems), anti-CD127-PE (BD Biosciences),
CD44-FITC (BD Biosciences), CD62L-FITC (BD Bio-
sciences), anti-LAP-PerCP (R&D Systems), anti-CD4-AF700
(Biolegend, San Diego, CA), and anti-CD25-APC-Cy7
(Biolegend). The cultured cells were collected at 72 hours or
at 48 hours for LAP staining, and washed once in ice cold
staining buﬀer (0.01M PBS with 1% BSA). The cells were
resuspend in staining buﬀer, and all the cells were stained for
CD25. The cells were costained for GITR, CTLA-4, CD44,
CD62L, or LAP. The cells were incubated with the antibodies
for 30 minutes on ice, washed twice with ice cold staining
buﬀer, and resuspended in staining buﬀer. The cells were
ﬁltered through nylon mesh and analyzed by ﬂow cytometry.
TheﬂowcytometrydatawasevaluatedusingFlowJosoftware
(Tree Star, Inc, Ashland, OR) gating on the CD25+ T cells.
All ﬂow cytometry results presented are representative of two
independent experiments.
2.3. Quantitative Real-Time PCR for FoxP3. Total RNA
was isolated from 4- and 24-hour-cultured T cells with
RNeasy mini kit (Qiagen Inc.,Valencia, CA) according to
the manufacturer’s instructions. The cells were washed three
times with PBS buﬀer and collected. They were disrupted,
lysed, and homogenized using a QIAshredder spin column
(Qiagen Inc.). An equal volume of 70% ethanol was mixed
with the homogenized lysates and applied to RNeasy mini
column for adsorption of total RNA to column membrane.
RNA was washed once with washing buﬀer. Further DNA
removal was done using a column DNase digestion by
RNase-Free DNase Set (Qiagen Inc.). RNA was washed and
eluted in RNase-free water. The RNA concentration was
determined by spectrophotometry at 260nm.
Theﬁrst-strandcDNAsynthesisreactionwasundertaken
with SuperScript First-Strand Synthesis System for RT-PCR
kit (Invitrogen, Carlsbad, CA). The isolated total RNA
(5μg) was reverse transcribed in a 20μL reaction mixture
containing20mMTris-HCl(pH8.4),50mMKCl,200μMof
each dNTP, 50ng of random hexamers, 5mM MgCl210mM
DTT, 40 units of RNaseOUT Recombinant Ribonuclease
Inhibitor, and 50 units of SuperScript II RT. The mixture
was incubated at 25◦Cf o r1 0m i na n dt r a n s f e r r e dt o4 2 ◦C
for 50min. The RT reaction was terminated by heating the
mixture to 70◦C for 15min and then adding 2 units of
RNase H at 37◦C for 20min to remove the RNA from the
cDNA:RNA hybrid molecule.Journal of Transplantation 3
The 50μL of real-time PCR reaction mixture consisted
of a FAM-dye labeled TaqMan MGB predesigned mouse
FoxP3 probe of two unlabeled PCR primers, FoxP3F
(5  CAGCTGCCTACAGTGCCCCTAG) and FoxP3R (5 
CATTTGCCAGCAGTGGGTAG), (Applied Biosystems, Fos-
ter City, CA), 25μL of 2X TaqMan Universal PCR Master
Mix containing AmpliTaq Gold DNA Polymerase, AmpErase
UNG, dNTPs with dUTP (Applied Biosystems), and 2μL
of our sample cDNA (equivalent to 500ng of RNA). The
ﬁnal reaction concentration of the probes was 250nM
and 900nM for each primer. Ampliﬁcation and detection
of PCR products were performed using an ABI Prism
7900HT Sequence Detection System with thermal cycling
conditions of: 2min at 50◦Cf o r1c y c l e ,1 0 m i na t9 5 ◦C
f o r1c y c l e ,1 5s e ca t9 5 ◦C, and 1min at 60◦Cf o r4 0c y c l e s .
The results were analyzed with SDS 2.1 software (Applied
Biosystems). Each assay was carried out in triplicate. The
relative expression of FoxP3 mRNA was normalized to the
relative expression of GAPDH mRNA (Applied Biosystems).
TherelativequantizationoftheFoxP3mRNAineachsample
was measured using the comparative Ct (threshold cycle)
method.
2.4. Sorting, Cytokine Production, and Regulatory T-Cell Assay
of α-MSH-Treated CD25− TC e l l s .Puriﬁed CD4+ Tc e l l s
were stained with anti-CD25-FITC (BD Biosciences) and
sorted on the Cytomation MoFlo Cell Sorter (Beckman
C o u l t e r ,B r e a ,C A ) .T h eC D 2 5 − T cells were collected, and
cultured at 4 × 105 cells per well of a 96 well plate. To
the cell cultures were added 1μg of anti-Tcr antibody, and
30pg/mL of α-MSH. After 48 hours, the supernatants were
collected and IFN-γ and TGF-β were measured. The IFN-
γ concentration was measured by ELISA using the R&D
System dual antibody kit. The TGF-β concentration was
measured using the standard MV1Lu bioassay [18]. To assay
for regulatory activity by the α-MSH-treated CD25− T cells,
the T cells were collected from the cell cultures and 2 ×
105 α-MSH-treated CD25− T cells were added to cultures
with 2 × 105 anti-Tcr-activated Th1 cells. After 48 hours of
incubation, IFN-γ production was measured by ELISA.
3. Results
3.1. Surface Marker Expression by α-MSH-Induced Treg Cells.
The α-MSH-induced Treg cells are CD25+ CD4+ Tc e l l s
previously demonstrated to be a stable population of T
cells that suppress the activation of inﬂammation mediated
by eﬀector T cells [16, 17, 28–30]. While it is considered
that CD25 is a marker of Treg cells, α-MSH-induced Treg
cells do not express CD25 any more than eﬀector T cells
[17]. Therefore, α-MSH-induced Treg cells were assayed and
compared to eﬀector T cells and resting T cells for CTLA4,
GITR, CD127, LAP, CD44, and CD62L, which are other
Treg and eﬀector T-cell activation markers. The α-MSH-
induced Treg cells were generated in vitro as done before by
treating Tcr-stimulated CD4+ eﬀector T cells with α-MSH at
a physiological concentration of 30pg/mL. After 72 hours,
the cells were stained and assayed by ﬂow cytometry gating
on the CD25+ T cells (Figure 1). There was no diﬀerence
foundintheexpressionofCTLA4,GITR,CD127,CD44,and
CD62L between the α-MSH induced Treg cells and eﬀector
Tc e l l s .T h ee ﬀector T cells and the α-MSH-induced Treg
cells expressed CTLA4, CD127, CD44, and CD62L but not
GITR. The cells had increased expression of CTLA4 and
CD62L with depressed expression of CD127 compared to
resting T cells. These results show that α-MSH-induced Treg
cells express markers associated with eﬀector T cells and not
necessarily markers of Treg cells. In addition, the regulatory
and eﬀector CD25+ CD4+ T cells expressed both CD44 and
CD62L suggesting that we may have induced T cells that
could also function as memory T cells.
Previously reported ﬁndings demonstrated that the sup-
pressive activity of α-MSH-induced Treg cells is mediated
through TGF-β [17]. Flow cytometry analysis for LAP
showed signiﬁcant diﬀerences in the surface expression of
LAP on the α-MSH-induced CD25+ CD4+ Treg cells to the
CD25+ CD4+ eﬀector T cells. The coexpression of CD25
and LAP shows that the α-MSH-induced CD25+ CD4+
Treg cells are highly expressive of LAP on their cell surface
(Figure 2). There was greater than 10-fold increase in LAP
expression on the α-MSH-induced Treg cells compared to
the stimulated eﬀector CD25+ CD4+ T cells. There is just
as striking an increase in LAP expression on α-MSH-treated
CD25− CD4+ T cells, suggesting that α-MSH has a general
eﬀect of increasing the number of T cells expressing LAP.
This could be due to increased availability of LAP for the
T cells to bind or to general induction of TGF-β even in
CD25− T cells. Therefore, while the α-MSH-induced Treg
cells express eﬀector and possible memory T-cell markers,
they diﬀer from eﬀector T cells by their surface expression
of LAP.
3.2. FoxP3 Expression in α-MSH Induced Treg Cells. The α-
MSH-induced Treg cells were assayed by RT-PCR for expres-
sion of FoxP3 message at 4 and 24 hours after treatment
(Figure 3). The α-MSH treatment induces a substantial early
2-fold upregulation in FoxP3 message in the activated T cells
that is relatively maintained 24 hours later. This suggests that
part of the mechanisms of α-MSH induction of regulatory
activityinvolvesFoxP3.TheuntreatedeﬀectorTcellsshowed
some increase in FoxP3 message that was less than the α-
MSH-treated cells but greater than unstimulated eﬀector T
cells (resting T cells). This suggests that, although α-MSH
treatment augments FoxP3 expression, there is naturally in
the untreated eﬀector T-cell population inducible FoxP3
expressing T cells.
3.3. The Eﬀects of α-MSH on CD25+ or CD25− TC e l l s .To
demonstrate that α-MSH treatment targets the activity of
activated eﬀector T cells, the eﬀector T cells (CD25+ T cells)
were removed from the collected draining lymph node CD4+
Tc e l l sb e f o r eα-MSH treatment. The unsorted population
of eﬀector T cells produced IFN-γ and TGF-β and when
treated with α-MSH produced only TGF-β (Figure 4(a))
similar to the cytokine production we have demonstrated
before between eﬀector T cells and α-MSH-induced Treg4 Journal of Transplantation
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Figure 1: Flow cytometry analysis of eﬀector/memory T-cell markers on α-MSH-induced Treg cells. Isolated draining lymph node CD4 T
cells from immunized mice were stimulated and treated with α-MSH (30pg/mL). After 72 hours of incubation, all the cells were stained
for CD25. The cells were also stained for CTLA4, GITR, CD127, CD44, or CD62L. The costained cells were analyzed by ﬂow cytometry.
Presented results are a representative of two experiments showing the histogram expression of CTLA4, GITR, CD127, CD44, or CD62L
on the gated CD25+ T-cell population. The gray shaded histograms are resting T cells; the thin lines are eﬀector T cells; the thick lines are
the α-MSH-induced Treg cells. There was no signiﬁcant diﬀerence in the expression of CTLA4, GITR, CD127, CD44, or CD62L on the
α-MSH-induced Treg cells compared to the stimulated eﬀector T cells.
cells [14, 16, 17, 24, 28, 30]. The collected CD4+ Tc e l l s
depleted of CD25+ T cells were completely devoid of all
eﬀector T-cell activity with no IFN-γ or TGF-β produced
(Figure 4(a)). Treating these CD25− CD4+ T cells with α-
MSH-induced TGF-β production. This corresponds with the
increase of LAP surface expression on CD25− T cells treated
with α-MSH seen in Figure 2. There was no expression of
CD25 on the α-MSH-treated and α-MSH-untreated sorted
T cells (data not shown). The α-MSH-treated CD25− T
cells did not suppress IFN-γ production by other Th1 cells
in culture (Figure 4(b)). Therefore, independent of α-MSH
induction of regulatory activity, α-MSH mediates TGF-β
production, and the α-MSH-induced Treg cells come from
α-MSH mediating regulatory activity in eﬀector T cells.
4. Discussion
The results in this paper propose that α-MSH induction
of regulatory immunity is mediated by α-MSH converting
eﬀector T cells. The α-MSH-induced Treg cells are CD25+
CD4+ expressing CTLA4, CD44, CD62L, and LAP. The
eﬀector CD25+ CD4+ T cells expressed the same markers
except for LAP. While α-MSH-induced TGF-β production,
it could not induce regulatory activity in naive T cells. This
limitation of α-MSH induction of regulatory activity in
eﬀector T cells and not in naive T cells has been observed
by us many times before but unreported. This implies that
the direct eﬀects of α-MSH on T cells are limited to antigen-
experienced eﬀector T cells. This explains why it is possible
to use α-MSH to induce antigen-speciﬁc Treg cells that
target antigen-driven autoimmunity, hypersensitivity, and
graft rejection [16, 17, 29, 30]. Such an eﬀect of α-MSH on
eﬀectorTcellshasimplicationsnotonlyonourowninterests
in ocular immune privilege but also on the role of α-MSH in
immune homeostasis.
Since it has been speculated that one of the systemic roles
of α-MSH is to promote resolution of inﬂammation [2], theJournal of Transplantation 5
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Figure 2: Flow cytometry analysis of LAP expression on α-MSH-induced Treg cells. The T cells were collected and treated as in Figure 1,
but were costained for CD25 and LAP. The ﬂow cytometry results are presented as dot plots showing T cells expressing CD25 and LAP
representing the results of two independent experiments. The expression of LAP on the eﬀector T cells decreases relative to the resting T
cells. In contrast, there is more than a 10-fold increase in LAP expression on α-MSH-induced Treg cells compared to the eﬀector T cells.
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Figure 3: Real-time PCR analysis of FoxP3 after α-MSH treatment.
The CD4+ T cells were isolated from draining lymph nodes,
stimulated and treated with α-MSH as before. At 4 hours and
24 hours after treatment, message was isolated and analyzed by
RT-PCR. Presented results are representative of two independent
experiments showing the relative levels of FoxP3 message in CD4+
T cells. There is consistently about a 2 fold-higher amount of FoxP3
message in the α-MSH-treated (+/+) than in the untreated eﬀector
Tc e l l s( −/+).
ability of α-MSH to induce regulatory activity in activated
eﬀector T cells would contribute to resolving inﬂammation.
The suppression of inﬂammation by α-MSH is a balance
between its antagonistic activity with proinﬂammatory
cytokines and activators of innate immunity. Therefore,
during the resolution phase as proinﬂammatory signals
decline, or are no longer present, the ability for α-MSH to
induce regulatory activity increases. Because we have found
that there is very little diﬀerence between eﬀector T cells
and the α-MSH-induced Treg cells except for their secreted
cytokine proﬁles and surface expression of LAP, it is to be
seen if the maintenance and activation of α-MSH-induced
Treg cells could also be in balance with proinﬂammatory
signals that drive adaptive immunity.
The constitutive presence of α-MSH within the ocular
microenvironment contributes to the immunosuppressive
mechanisms of ocular immune privilege [14]. The neu-
ropeptide is part of the active ocular mechanisms that sup-
press eﬀector T-cell activation [32]. Moreover, the presence
of α-MSH is part of the mechanisms used by the ocular
microenvironment to turn immunity onto itself, should
eﬀector cells be activated within the ocular microenviron-
ment [33]. Recently found are the presence of autoantigen-
speciﬁc Treg cells within the spleens of mice that have
naturally recovered from ocular autoimmune disease [21].
Their presence in the spleen is dependent on the expres-
sion of MC5r, the receptor on T cells through which
α-MSH induces regulatory activity [20]. In addition, α-
MSH treatment of mice with experimental autoimmune
encephalomyelitis(EAE)notonlypreventedfurtherparalysis
but also promoted an early recovery of full-motor function
[24]. Moreover, in the spleens of these α-MSH-treated mice
were Treg cells that suppress EAE. Therefore, augmenting α-
MSH has the potential to promote activation of regulatory
activity in eﬀector T cells during an inﬂammatory response.
Also,itappearsthatoncetheTcellsaresetinthisdirection,it
may be diﬃcult for α-MSH-induced Treg cells to revert back
into eﬀector T cells.
Very little is understood about the intracellular signals
triggered by α-MSH within T cells. The melanocortin re-
ceptors are G-coupled protein receptors that elevate cAMP
when bound with α-MSH [34]; however, this alone cannot
account for all the actions induced by α-MSH in T cells.
The induction of regulatory activity by α-MSH in T cells is
through MC5r [17]. When α-MSH binds MC5r it has been
found to activate within immune cells the JAK2/STAT1 and
ERK1/2pathways[35,36].Therefore,α-MSHthroughMC5r6 Journal of Transplantation
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Figure 4: The eﬀects of α-MSH on CD25− CD4+ T cells. The CD4 T cells were isolated from the draining lymph node as in Figure 1 and
were stained with CD25 antibody. The stained cells were sorted, and the CD25− cells were placed in culture, stimulated, and treated with
α-MSH. (a) After 48 hours, the supernatant was assayed for IFN-γ and TGF-β.T h es o r t e dC D 2 5 − CD4+ T cells (Sorted) did not produce
IFN-γ or TGF-β; however, when treated with α-MSH (Sorted + MSH) did produce TGF-β but not IFN-γ.( b )T h eα-MSH-treated CD25−
CD4+ T cells were transferred to cultures of activated Th1 cells. After 48 hours of incubation IFN-γ was measured in the supernatant. There
was no statistical diﬀerence in IFN-γ production by the Th1 cells in culture with or without α-MSH-treated CD25− CD4+ Tc e l l s .
is at least potentially linked to signals that mediate cellular
diﬀerentiation and cytokine production. What is not known
is how this is linked to α-MSH-mediated induction of Treg
cells.
The α-MSH-induced Treg cells are T cells that retain
several features of eﬀector T cells and have also features
and functions associated with natural and inducible Treg
cells. Previous publications have shown that the α-MSH-
induced Treg cells are limited in cytokine production to
TGF-β, proliferate, must be activated through their Tcr to
mediate regulatory activity, and their induction is dependent
on the expression of MC5r [17]. To these ﬁndings the α-
MSH-induced Treg cells express surface LAP, corresponding
totheiruseofTGF-βtosuppresseﬀectorTcellsthroughcon-
tact or enhanced release of active TGF-β [17]. Also, the α-
MSH-induced Treg cells are from the eﬀector CD25+ CD4+
T-cell population indicating α-MSH-mediated conversion of
eﬀector T cells into Treg cells.
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